Anthracycline-Induced Cardiotoxicity
Authors: Laurel J. Steinherz
Journal: Annals of Internal Medicine (1997)

Letters15 May 1997Anthracycline-Induced CardiotoxicityLaurel J. Steinherz, MDLaurel J. Steinherz, MDMemorial Sloan-Kettering Cancer Center, New York, NY 10021Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-10-199705150-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Shan and colleagues [1] provided a thorough, insightful, and well-balanced review of anthracycline cardiomyopathy. However, the discussion of the clinical significance of late-onset cardiotoxicity presented some confusing information that needs to be clarified. The authors stated that "new-onset symptomatic ventricular dysfunction was not seen until 12 to 14 years after treatment in the study by Lipshultz and coworkers." However, the symptomatic patients reported by Lipshultz and colleagues actually had "recurrent heart failure 3.7 to 10.3 years after completing doxorubicin treatment, and … [n]o patient had late heart failure as a new event" [2]. In fact, the patients ...References1. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996; 125:47-58. Google Scholar2. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991; 324:808-15. Google Scholar3. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266:1672-7. Google Scholar4. Steinherz LJ, Steinherz PG, Sklar C, Wollner N, Tan C. Cardiac status of 42 patients ≥ 15 years post anthracycline therapy [Abstract]. Med Pediatr Oncol. 1994;23:176. Google Scholar5. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for the treatment of acute lymphoblastic leukemia in children at increased risk of early relapse: The MSK-New York-II protocol. Cancer. 1993; 72:3120-30. Google Scholar Author, Article, and Disclosure InformationAffiliations: Memorial Sloan-Kettering Cancer Center, New York, NY 10021 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByCardiovascular effects of Hodgkin's lymphoma: a review of literatureUsing cardiac biomarkers and treating cardiotoxicity in cancerUnderstanding the binding of daunorubicin and doxorubicin to NADPH-dependent cytosolic reductases by computational methodsICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection ContextClinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiationCardiovascular and Pulmonary Late EffectsAdjuvant ChemotherapyAre We Improving the Long-Term Burden of Hodgkin's Lymphoma Patients with Modern Treatment?Late cardiotoxicity after treatment for Hodgkin lymphomaLevocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigueEnalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to AnthracyclinesUse of stress echocardiography for planning and evaluation of interventions and medical treatmentDesign and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivorsA Critical Risk-Benefit Assessment Argues Against the Use of Anthracyclines in Induction Regimens for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia 15 May 1997Volume 126, Issue 10Page: 827KeywordsCardiomyopathiesChemotherapyChildrenHeartHeart failurePatientsYoung adults Issue Published: 15 May 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...